Combinatorial nanotherapeutics: Rewiring, then killing, cancer cells

Science Signaling

Volumn 7, Issue 325, 2014, Pages

  Fang, Ronnie H ^a   Zhang, Liangfang ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ERLOTINIB; NANOPARTICLE; ANTINEOPLASTIC AGENT; DRUG CARRIER;

APOPTOSIS; CANCER CELL; CANCER RESISTANCE; CELL KILLING; CONTROLLED DRUG RELEASE; DNA DAMAGE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GENOTOXICITY; HUMAN; NANOTECHNOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; ANIMAL; FEMALE; NEOPLASMS, EXPERIMENTAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG CARRIERS; FEMALE; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL;

EID: 84900525376     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2005386     Document Type: Short Survey

References (12)

1. M. M. Gottesman, Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627 (2002).
2. C. R. Chong, P. A. Jänne, The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 19, 1389-1400 (2013).
3. D. A. Nathanson, B. Gini, J. Mottahedeh, K. Visnyei, T. Koga, G. Gomez, A. Eskin, K. Hwang, J. Wang, K. Masui, A. Paucar, H. J. Yang, M. Ohashi, S. J. Zhu, J. Wykosky, R. Reed, S. F. Nelson, T. F. Cloughesy, C. D. James, P. N. Rao, H. I. Kornblum, J. R. Heath, W. K. Cavenee, F. B. Furnari, P. S. Mischel, Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343, 72-76 (2014).
4. K. Yonesaka, K. Zejnullahu, I. Okamoto, T. Satoh, F. Cappuzzo, J. Souglakos, D. Ercan, A. Rogers, M. Roncalli, M. Takeda, Y. Fujisaka, J. Philips, T. Shimizu, O. Maenishi, Y. G. Cho, J. S. Sun, A. Destro, K. Taira, K. Takeda, T. Okabe, J. Swanson, H. Itoh, M. Takada, E. Lifshits, K. Okuno, J. A. Engelman, R. A. Shivdasani, K. Nishio, M. Fukuoka, M. Varella-Garcia, K. Nakagawa, P. A. Jänne, Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 3, 99ra86 (2011).
5. B. Y. Zhao, J. R. Pritchard, D. A. Lauffenburger, M. T. Hemann, Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov. 4, 166-174 (2014).
6. B. Al-Lazikani, U. Banerji, P. Workman, Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 30, 679-692 (2012).
7. M. J. Lee, A. S. Ye, A. K. Gardino, A. M. Heijink, P. K. Sorger, G. MacBeath, M. B. Yaffe, Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794 (2012).
8. M. E. Davis, Z. G. Chen, D. M. Shin, Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771-782 (2008).
9. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, R. Langer, Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007).
10. D. J. Irvine, Drug delivery: One nanoparticle, one kill. Nat. Mater. 10, 342-343 (2011).
11. C.-M. J. Hu, L. F. Zhang, Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 83, 1104-1111 (2012).
12. S. W. Morton, M. J. Lee, Z. J. Deng, E. C. Dreaden, E. Siouve, K. E. Shopsowitz, N. J. Shah, M. B. Yaffe, P. T. Hammond, A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci. Signal. 7, ra44 (2014).